可切除进展期胃癌的新辅助多西他赛、奥沙利铂和替吉奥联合手术及术后替吉奥辅助治疗:III期PRODIGY研究更新的总生存结果
III期PRODIGY研究纳入可切除局部进展期胃癌(临床T2-3N+或T4Nany)患者,比较新辅助多西他赛+奥沙利铂+替吉奥(DOS)后手术及术后替吉奥(CSC)与手术及术后替吉奥(SC)。CSC组238例、SC组246例,中位随访99.5个月,CSC显著改善总生存(校正HR 0.72,分层log-rank P=0.027),8年OS率63.0% vs 55.1%。
要点
- 新辅助DOS化疗联合手术及术后替吉奥较手术及术后替吉奥显著延长总生存(校正HR 0.72,P=0.027)。
- CSC组8年OS率为63.0%,SC组为55.1%。
- CSC组无进展生存也显著改善(HR 0.70,P=0.016)。
核心结论
- 新辅助DOS化疗作为围手术期化疗的一部分,较手术及术后替吉奥延长了亚洲局部进展期胃癌患者的总生存。
- 作者认为应考虑将其作为亚洲局部进展期胃癌患者的标准治疗选择之一。
研究设计与样本
- III期PRODIGY研究,可切除局部进展期胃癌(临床T2-3N+或T4Nany)患者随机分配至CSC组238例和SC组246例并接受治疗(全分析集)。
- 主要终点为无进展生存,总生存为次要终点,本次报告长期随访的总生存结果。
- 数据截止时间为2022年9月,存活患者的中位随访时间为99.5个月。
主要发现
- CSC组与SC组相比显著改善总生存(校正HR 0.72,分层log-rank P=0.027)。
- CSC组8年总生存率为63.0%,SC组为55.1%。
- CSC组无进展生存也显著改善(HR 0.70,分层log-rank P=0.016)。
临床怎么用
- 作者认为,新辅助DOS化疗作为围手术期化疗的一部分,应考虑作为亚洲局部进展期胃癌患者的标准治疗选择之一。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The phase III PRODIGY study demonstrated that neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery and adjuvant S-1 chemotherapy (CSC) improved progression-free survival (PFS) compared with surgery followed by adjuvant S-1 (SC) for patients with resectable locally advanced gastric cancer (LAGC) with clinical T2-3N+ or T4Nany disease. The primary end point was PFS. Overall survival (OS) was the secondary end point. We herein report the long-term follow-up outcomes, including OS, from this trial. A total of 238 and 246 patients were randomly assigned to the CSC and SC arms, respectively, and were treated (full analysis set). As of the data cutoff (September 2022), the median follow-up duration of the surviving patients was 99.5 months. Compared with SC, CSC significantly increased the OS (adjusted hazard ratio [HR], 0.72; stratified log-rank P = .027) with an 8-year OS rate of 63.0% and 55.1% for the CSC and SC arms, respectively. CSC also significantly improved the PFS (HR, 0.70; stratified log-rank P = .016). In conclusion, neoadjuvant DOS chemotherapy, as part of perioperative chemotherapy, prolonged the OS of Asian patients with LAGC relative to patients treated with surgery and adjuvant S-1. It should be considered one of the standard treatment options for patients with LAGC in Asia.
引用
- Kang YK, Kim HD, Yook JH, et al. Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY. J Clin Oncol. 2024. PMID: 38996201. doi:10.1200/JCO.23.02167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。